Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Letters to the Editor - Letter in Response to Previously Published Articles
2019:85:1;84-85
doi: 10.4103/ijdvl.IJDVL_927_18
PMID: 30560813

Author's reply

Sanjay Singh
 Department of Dermatology and Venereology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Correspondence Address:
Sanjay Singh
Department of Dermatology and Venereology, Institute of Medical Sciences, Banaras Hindu University, Varanasi - 221 005, Uttar Pradesh
India
Published: 13-Dec-2018
How to cite this article:
Singh S. Author's reply. Indian J Dermatol Venereol Leprol 2019;85:84-85
Copyright: (C)2019 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

It is a pleasure to reply to the comments on our article[1] and I thank you for the opportunity to make this humble submission.

What did we do?

As mentioned,[1] the study was performed to find evidence for or against the perceived loss of effectiveness of terbinafine in tinea infections in India. We presented the first data and said that terbinafine is not working in real-world setting. That is all.

Did we speculate about the causes of ineffectiveness of terbinafine?

We did not speculate about the causes, which may be many, nor did we mention that the cause of abysmal effectiveness is drug resistance. In fact, the word “resistance” is missing from the article. And would it not be in the fitness of things to wait for future research to find the answers?

Comparison with commentators' onychomycosis study

Commentators say that in their onychomycosis study, “patients were normally treated according to the British guidelines”. The guidelines recommend oral terbinafine for 6 weeks in fingernail and for 12–16 weeks in toenail infection.[2] Two other sentences cloud the issue of how long the treatment was given, these are, “only 24.3% of the patients, responded to treatment after 6 months” and “21% of them said they only received a treatment for <4 months”. Was the duration of treatment 6 months? In any case, the duration of treatment was much longer than 4 weeks.

Comparing the commentators' onychomycosis study with ours is comparing dissimilar studies. Cure rates of tinea corporis/cruris/faciei and onychomycosis cannot be compared. Chances of poor compliance occurring in their study of long treatment duration are much higher than in our study of 4 weeks. Also, the causes of poor compliance found in their study (cost of drug and fear of adverse effects), being dependent on duration of treatment, would be minimal and inconsequential in our study. Furthermore, it is hard to believe that the patients of our study were coming for follow-ups but were not taking treatment. I refrain from commenting further because (a) the data provided are thin and (b) reference to the study is not available.

Does poor compliance as the cause of ineffectiveness of terbinafine really stand up to scrutiny?

A mini thought experiment, comprising two invariables (excellent effectiveness of terbinafine until recent past and its dramatic decline now) and a hypothetical antecedent to the second event (poor compliance), will shed some light on the issue. To accept that the hypothetical antecedent happened and caused the second event, we must accept that a couple of years ago, almost precipitously, profound unidirectional change in treatment-taking behavior of patients living over a large land mass occurred. Now, you see the problem, and the implausibility of poor compliance explaining the lack of effectiveness of terbinafine, as of now and pending new evidence, becomes apparent. Poor compliance may have contributed, but the chances of it being the sole or main cause are slim.

“End of the road?” or “End of the road”?

The only place where we used the phrase “end of the road” in the article is the title. There too it was “End of the road for terbinafine?” (note the question mark, which makes the phrase open-ended, interrogative and in the spirit of enquiry), and not “End of the road for terbinafine” (which would be affirmative). The difference between the two may be appreciated.

The big question

In the last analysis, following questions present themselves: Should a drug, which has been shown to be ineffective in clinical trial, be considered effective based on in vitro studies (in case the fungus is susceptible)? Is it not the clinical trial that is the final arbiter on the effectiveness of a drug? This is the question.

Let us go where the data take us.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References
1.
Singh S, Shukla P. End of the road for terbinafine? Results of a pragmatic prospective cohort study of 500 patients. Indian J Dermatol Venereol Leprol 2018;84:554-7.
[Google Scholar]
2.
Ameen M, Lear JT, Madan V, Mohd Mustapa MF, Richardson M. British Association of Dermatologists' guidelines for the management of onychomycosis 2014. Br J Dermatol 2014;171:937-58.
[Google Scholar]

Fulltext Views
351

PDF downloads
294
Show Sections